Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Matteo Serenelli

Showing results (81-90 of 84) with videos related to

Pageof 9
Sort By:
You have reached the last page of results.This site can display upto 84 results.
Journal of Cardiovascular Medicine (Hagerstown, Md.)|February 17, 2026
Acute coronary syndrome and coronary artery disease in wild-type transthyretin amyloid cardiomyopathy: a DIAMOND sub-studyLaura De Michieli, Giacomo Tini, Alessia Argirò, et al.
JACC. Heart Failure|July 3, 2025
Outcome and Disease Progression in NYHA Functional Class I and II Patients With Wild-Type Transthyretin Cardiomyopathy Treated With TafamidisGiulio Sinigiani, Giuseppe Damiano Sanna, Alberto Aimo, et al.
Journal of Cardiovascular Medicine (Hagerstown, Md.)|November 26, 2025
Neurohormonal therapies at baseline and follow-up and survival in wild-type transthyretin cardiac amyloidosisAlberto Aimo, Paolo Milani, Giacomo Tini, et al.
ESC Heart Failure|September 20, 2024
Early diagnosis, disease stage and prognosis in wild-type transthyretin amyloid cardiomyopathy: The DIAMOND studyGiacomo Tini, Beatrice Musumeci, Paolo Milani, et al.
Pageof 9

Showing results (81-90 of 84) with videos related to

Sort By:
Pageof 9
You have reached the last page of results.This site can display upto 84 results.
Journal of Cardiovascular Medicine (Hagerstown, Md.)|February 17, 2026
Acute coronary syndrome and coronary artery disease in wild-type transthyretin amyloid cardiomyopathy: a DIAMOND sub-studyLaura De Michieli, Giacomo Tini, Alessia Argirò, et al.
JACC. Heart Failure|July 3, 2025
Outcome and Disease Progression in NYHA Functional Class I and II Patients With Wild-Type Transthyretin Cardiomyopathy Treated With TafamidisGiulio Sinigiani, Giuseppe Damiano Sanna, Alberto Aimo, et al.
Journal of Cardiovascular Medicine (Hagerstown, Md.)|November 26, 2025
Neurohormonal therapies at baseline and follow-up and survival in wild-type transthyretin cardiac amyloidosisAlberto Aimo, Paolo Milani, Giacomo Tini, et al.
ESC Heart Failure|September 20, 2024
Early diagnosis, disease stage and prognosis in wild-type transthyretin amyloid cardiomyopathy: The DIAMOND studyGiacomo Tini, Beatrice Musumeci, Paolo Milani, et al.
Pageof 9